Growth factors in benign prostatic hyperplasia: Basic science implications

被引：20

作者：

Lucia M.S. ^{[1
]}

Lambert J.R. ^{[1
]}

机构：

[1] Department of Pathology, University of Colorado DHSC, Mail Stop 8104, Aurora, CO 80045

来源：

Current Urology Reports | 2008年 / 9卷 / 4期

关键词：

Vascular Endothelial Growth Factor; Benign Prostatic Hyperplasia; Keratinocyte Growth Factor; Prostatic Epithelial Cell; Prostatic Stromal Cell;

D O I：

10.1007/s11934-008-0048-6

中图分类号：

学科分类号：

摘要：

Benign prostatic hyperplasia (BPH) is the most common proliferative disease of the prostate of men in the United States. The histopathology of BPH strongly implicates local paracrine and autocrine growth factors and inflammatory cytokines in its pathogenesis. A complex milieu of growth-regulatory proteins includes members of the fibroblast, insulin-like, and transforming growth factor families. It appears that these proteins and downstream effector molecules, in addition to a variety of interleukins, are overexpressed in BPH and, working together, create a landscape of increased stromal and epithelial growth and mesenchymal transdifferentiation that leads to disease progression. Inflammation, commonly present in BPH, may contribute to tissue injury, and cytokines produced by inflammatory cells may serve to drive local growth factor production and angiogenesis in the tissues as a "wound healing" response. As we begin to unravel the precise mechanisms involved, new treatments for BPH aimed at these interacting pathways may emerge. Copyright © 2008 by Current Medicine Group LLC.

引用

页码：272 / 278

页数：6

共 50 条

[1]

Berry S.J., Coffey D.S., Walsh P.C., Et al., The development of human benign prostatic hyperplasia with age, J Urol, 132, pp. 474-479, (1984)

[2]

Kirby R.S., The natural history of benign prostatic hyperplasia: What have we learned in the last decade?, Urology, 56, pp. 3-6, (2000)

[3]

Lee C., Kozlowski J.M., Grayhack J.T., Intrinsic and extrinsic factors controlling benign prostatic growth, Prostate, 31, pp. 131-138, (1997)

[4]

McNeal J., Pathology of benign prostatic hyperplasia: Insight into etiology, Urol Clin North Am, 17, pp. 477-486, (1990)

[5]

Bierhoff E., Walljasper U., Hofmann D., Et al., Morphological analogies of fetal prostate stroma and stromal nodules in BPH, Prostate, 31, pp. 234-240, (1997)

[6]

Giri D., Ropiquet F., Ittmann M., Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer, Clin Cancer Res, 5, pp. 1063-1071, (1999)

[7]

Ropiquet F., Giri D., Lamb D.J., Et al., FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation, J Urol, 162, pp. 595-599, (1999)

[8]

Nishi N., Matuo Y., Muguruma Y., Et al., A human prostatic growth factor (hPGF): Partial purification and characterization, Biochem Biophys Res Commun, 132, pp. 1103-1109, (1985)

[9]

Ittman M., Mansukhani A., Expression of fibroblast growth factors (FGFs) and FGF receptors in human prostate, J Urol, 157, pp. 351-356, (1997)

[10]

Boget S., Cereser C., Parvaz P., Et al., Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-IIIc and FGFR3 are, Eur J Endocrinol, 145, pp. 303-310, (2001)

← 1 2 3 4 5 →